# CDH1

Source: https://onco.cc/targets/cdh1/  
OnCo record `cdh1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.

## Summary

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells.

CIViC holds 8 clinical evidence items and 0 assertions across 6 variants, naming Crizotinib, Pazopanib, Foretinib and Palbociclib Regimen. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes genetic literature 0.82, affected pathway 0.54, literature 1.00, genetic association 0.83, somatic mutation 0.96). IntOGen calls it a driver in 18 cohorts (3 activating, 14 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cutaneous Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma, Stomach Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cadherin 1; Cadherin-1; uvomorulin; CD324
- Tags: cancer-genes-wave
- Symbol: CDH1
- Class: tumor-suppressor
- Biology: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Promotes organisation of radial actin fibre structure and cellular response to contractile forces, via its interaction with AMOTL2 which facilitates anchoring of radial actin fibres to CDH1 junction complexes at the cell membrane. Plays a role in the early stages of desmosome cell-cell junction formation via facilitating the recruitment of DSG2 and DSP to desmosome plaques. Has a potent invasive suppressor role. Location: Cell junction, adherens junction; Cell membrane; Endosome; Golgi apparatus, trans-Golgi network (UniProt). Locus 16q22.1 (HGNC).
- Where found: Gastric & gastro-oesophageal junction cancer: Open Targets association 0.84 with gastric cancer (MONDO_0001056); CIViC evidence names this disease; Breast cancer: Open Targets association 0.82 with breast cancer (MONDO_0007254); CIViC evidence names this disease; Ovarian cancer: Open Targets association 0.72 with ovarian cancer (MONDO_0008170); Endometrial cancer: Open Targets association 0.71 with endometrial cancer (MONDO_0011962); Prostate cancer: Open Targets association 0.67 with prostate cancer (MONDO_0008315); Bladder & urothelial cancer: IntOGen driver in 2 cohorts (BLCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 14 cohorts; CIViC holds 8 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1748: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1748
- UniProt P12830: https://www.uniprot.org/uniprotkb/P12830/entry
- NCBI Gene 999: https://www.ncbi.nlm.nih.gov/gene/999
- Ensembl ENSG00000039068: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000039068

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- pathways: [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/)

---
JSON: https://onco.cc/api/v1/entities/cdh1.json